Etoricoxib as a treatment of choice for patients with SLCO2A1 mutation exhibiting autosomal recessive primary hypertrophic osteoarthropathy: A case report

Etoricoxib as a treatment of choice for patients with SLCO2A1 mutation exhibiting autosomal recessive primary hypertrophic osteoarthropathy: A case report

We reported a 22-year-old Emirati male with autosomal recessive primary hypertrophic osteoarthropathy caused by a possibly pathogenic homozygous non-synonymous variant in the SLCO2A1 gene (NM_005630.3: c.289C>T, p. Arg97Cys) presenting with joint swelling, forehead furrowing, and significant...

Full description

Bibliographic Details
Main Authors: Areej Albawa'neh, Mariam Ghareeb Al Mansoori, Sehriban Diab, Fatma Al Jasmi, Nadia Akawi
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-12-01
Series:Frontiers in Genetics
Subjects:
autosomal recessive primary hypertrophic osteoarthropathy
SLCO2A1 gene
etoricoxib
PGE2
digital clubbing
Online Access:https://www.frontiersin.org/articles/10.3389/fgene.2022.1053999/full

Internet

https://www.frontiersin.org/articles/10.3389/fgene.2022.1053999/full

Similar Items